Switching transplant drug may cut skin cancer risk
NCT ID NCT00133887
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This study looked at kidney transplant patients who already had one skin cancer. It compared switching their anti-rejection medicine to rapamycin versus staying on standard drugs. The goal was to see if rapamycin could prevent new skin cancers over two years while keeping the transplanted kidney healthy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Edouard Herriot - Service de Dermatologie
Lyon, 69003, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.